Bristol Myers CAR-T therapy shows high response rate in treatment-resistant blood cancer

Bristol Myers Squibb announced on September 8, 2026, that its experimental CAR-T cell therapy, arlocabtagene autoleucel (arlo-cel), achieved a high overall response rate in a mid-stage trial. The study evaluated the single-infusion therapy, which targets the GPRC5D protein, in patients with advanced multiple myeloma who had failed at least four prior standard treatments. While specific numerical data was withheld, the trial met its primary endpoint and completely cleared detectable cancer in some patients, offering hope against a disease expected to cause 11,000 U.S. deaths in 2026.

Arlo-cel mid-stage trial results

• ▪The mid-stage trial of arlocabtagene autoleucel met a key secondary endpoint by completely clearing detectable signs of cancer in some patients
• ▪Bristol Myers Squibb announced on September 8, 2026, that its experimental cell therapy, arlocabtagene autoleucel, showed a high overall response rate in a mid-stage trial
• ▪The mid-stage trial of arlocabtagene autoleucel met its primary endpoint by showing a statistically significant and clinically meaningful improvement in the overall response rate
• ▪The safety profile of arlocabtagene autoleucel in the mid-stage trial was consistent with expectations and in line with other CAR-T and GPRC5D-targeting therapies
• ▪Bristol Myers Squibb did not release specific numerical data from the trial but announced plans to present the full findings at an upcoming medical meeting

GPRC5D-targeted CAR-T mechanism

• ▪Arlocabtagene autoleucel is a CAR-T cell therapy administered to patients as a single infusion
• ▪The personalized treatment arlocabtagene autoleucel works by extracting a patient's own immune cells, modifying them in a laboratory to target the GPRC5D protein on cancer cells, and infusing them back into the body

Treatment-resistant multiple myeloma patient population

• ▪According to Endpoints News, a major ongoing concern in blood cancer treatment is determining alternative options for multiple myeloma patients whose cancers progress after receiving CAR-T therapy
• ▪The mid-stage trial evaluated arlocabtagene autoleucel in patients with advanced multiple myeloma who had already tried at least four major classes of standard treatments without lasting success

Multiple myeloma disease burden

• ▪The American Cancer Society estimated that approximately 36,000 new cases and nearly 11,000 deaths from multiple myeloma would occur in the United States in 2026
• ▪Multiple myeloma is a type of blood cancer that forms in plasma cells, which are a type of white blood cell

Debatable claims

• ▪Bristol Myers Squibb should have released numerical data alongside its trial success announcement
• ▪CAR-T therapies should be reserved as a last resort for advanced cancer patients

3 sources